Clinical trials: Steatosis of Liver
Nonalcoholic Steatohepatitis (NASH)
Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients
We conducted a 3-month, randomized, single-blind study in 102 Egyptian NASH patients who were divided into three groups; group 1 included 34 patients received Vit.
- Trial name
- NCT04977661
- Testing
- Vitamin E, Ursodeoxycholic acid, Pentoxifylline
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Kafrelsheikh University
Non-Alcoholic Fatty Liver
Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an…
- Trial name
- NCT03953456
- Testing
- elafibranor 120mg
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Genfit
NAFLD, Alcohol-Related Disorder
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study)
The main objective is to determine the performance of the simple eLIFT blood test for advanced liver fibrosis screening in NAFLD and/or alcoholic patients in primary care.
- Conditions
- NAFLD, Alcohol-Related Disorder, Liver Fibrosis
- Trial name
- IMPROVE (NCT04146636)
- Testing
- e-LIFT
- Where
- France
- Volunteers
- 282 people
- Sponsor
- University Hospital, Angers
Non-Alcoholic Fatty Liver Disease
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.
- Trial name
- NCT03350165
- Testing
- K-877
- Where
- 16 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Kowa Company, Ltd.
Non-Alcoholic Steatohepatitis (NASH)
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
- Trial name
- IMPACT (NCT05989711)
- Testing
- Pemvidutide
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 212 people
- Sponsor
- Altimmune, Inc.
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Non-Alcoholic Fatty Liver Disease, Obesity
Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).
Nonalcoholic steatohepatitis is a growing public health problem affecting over 5% of the population. These patients are at increased risk of cardiovascular and liver-related death and have higher rates of malignancy.
- Trial name
- NASH-APOLLO (NCT03426111)
- Testing
- Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA), Lifestyle modification
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Puerta de Hierro University Hospital
Non Alcoholic Steatohepatitis (NASH)
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis…
- Trial name
- NCT04880187
- Testing
- AXA1125
- Where
- 75 sites in United States, Australia and 5 more
- Volunteers
- 273 people
- Sponsor
- Axcella Health, Inc
Non Alcholic Fatty Liver Disease
Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease
This is a Phase III, multicentre, randomized, double-blind, placebo-controlled, interventional study designed to evaluate the efficacy and safety of a standardized fraction of Picrorhiza kurroa Royal Ex Benth (Picroliv®) in…
- Trial name
- NCT07452744
- Testing
- Picroliv
- Where
- 6 sites in India
- Volunteers
- 170 people
- Sponsor
- Bioagile Therapeutics Pvt. Ltd.
NASH, NAFLD
Digoxin In NASH (CODIN)
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans.
- Conditions
- NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash
- Trial name
- CODIN (NCT06588699)
- Testing
- Digoxin
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Non-Alcoholic Fatty Liver Disease
The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD?
The goal of this clinical trial is to investigate the different effect of morning and evening exercise training in individuals with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- TikTac (NCT05987748)
- Testing
- Exercise training
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Leiden University Medical Center
Effects of Bacillus Coagulans TCI711 Supplementation on Liver and Gut Microbiota Function in Non-alcoholic Fatty Liver Disease Patients
Effects of Bacillus Coagulans on Liver and Gut Microbiota Function in NAFLD
According to the 2018 statistics of the American Association of Liver Diseases, about 25% of the world's population has non-alcoholic fatty liver disease, and about 10 to 20% of patients with simple fatty liver will develop…
- Trial name
- NCT05635474
- Testing
- Bacillus Coagulans
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University
Diabetes Mellitus Type 2, Metabolic Syndrome
Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
The most important cause of mortality amongst DM2 patients is cardiovascular disease. An early finding of cardiovascular disease in DM2 and obesity is diastolic dysfunction.
- Conditions
- Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction
- Trial name
- MAGNA VICTORIA (NCT01761318)
- Testing
- Liraglutide
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Leiden University Medical Center
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis
Tocotrienol Against the Progression of End Stage Liver Disease
The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis.
- Conditions
- End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
- Trial name
- NCT02581085
- Testing
- Tocotrienol (TCT)
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Chandan Sen
Hepatic Steatosis, Overweight and Obesity
Implementation of the Fatty Liver Index in Primary Care
This trial aims to evaluate the impact on cardiovascular risk control in individuals in risk of being affected by hepatic steatosis through the implementation of a screening test (Fatty Liver Index) in Primary Care.
- Trial name
- FLI-AP (NCT06363617)
- Testing
- FLI
- Where
- Spain
- Volunteers
- 434 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Nonalcoholic Fatty Liver Disease (NAFLD)
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD).
- Trial name
- CyNCh (NCT01529268)
- Testing
- DR cysteamine bitartrate capsule
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NAFLD
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.
- Trial name
- NCT04634643
- Testing
- Usual diet and physical activity
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Yale University
Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Dairy Protien Rich Diet for NAFLD Patients
The overarching aim of this project is to investigate effects of dietary interventions on nonalcoholic fatty liver disease (NAFLD) severity and to delineate the relationship with improvements in metabolic aberrations in liver…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome, Caseins, Whey
- Trial name
- DAIPRO-NAFLD (NCT04841915)
- Testing
- High-Protein Diet, Clinical dietician, Weight loss
- Where
- 2 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
HIV Infections, Non-Alcoholic Fatty Liver Disease
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
- Trial name
- NCT04216589
- Testing
- Semaglutide
- Where
- 9 sites in United States, Brazil
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)